Hodgkin lymphoma outcomes in the novel agent era, genomic safe harbors for precision T cell engineering, and a transcriptomic atlas to map imatinib resistance in CML

episode

Blood Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Booked out doesn't mean you're ready for an associate OD 23 min · 23 Sep 2026 · The Optometry Success Podcast

Alt.Latino: YEИDRY's life in six songs 38 min · 23 Sep 2026 · NPR Music

Neil Young 1h 33m · 23 Sep 2026 · Tetragrammaton with Rick Rubin

Warnings (PODCAST EXCLUSIVE EPISODE) 27 min · 23 Sep 2026 · MrBallen Podcast: Strange, Dark & Mysterious Stories

Larry the Cable Guy on His Origin Story, Blue-Collar Comedy & Buckin’ Bulls! 1h 47m · 23 Sep 2026 · Adam Carolla Show

Gaining an edge in Financial Markets with Mike Bell, CFA - Part 2 37 min · 23 Sep 2026 · The MOST Important Thing

Report any issue

Source

Recorded01 Jun 2023

Publisherfeeds.transistor.fm ↗

Handlerec:11742023

Show notes

In this week’s episode, we'll discuss how patients with relapsed or refractory Hodgkin lymphoma survival outcomes have improved after development of several novel agents. Next, precision engineering of therapeutic T cells through extragenic safe harbors. Finally, using a single-cell atlas to map features of imatinib resistance in diagnostic CML bone marrow, investigators present gene expression signatures predictive of response to TKI therapy.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in